LYRA / Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients

Lyra Therapeutics has two product candidates in clinical trials for Chronic rhinosinusitis (CRS) patients. Both candidates, LYR-210 and LYR-220, show more_horizontal

Lyra Therapeutics' LYR-220 shows promise in addressing chronic rhinosinusitis, targeting a patient demographic that doesn't respond to current treatme more_horizontal

Lyra (LYRA) gains on positive data from mid-stage study of LYR-220, treating patients with chronic rhinosinusitis who have had ethmoid sinus surgery. more_horizontal

Friday's impressive 13% surge in the shares of Lyra Therapeutics (US:LYRA) carried over into the new week as investors pushed the LYRA stock price up more_horizontal

Lyra Therapeutics, Inc. (LYRA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares more_horizontal

Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the more_horizontal

Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common more_horizontal

Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS more_horizontal